（文章来源：证券日报） 证券日报网讯 12月3日，葵花药业在互动平台回答投资者提问时表示，截至11月28日，公司股东人数为 5.1万户。 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-078 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会 议、第五届监事会第四次会议、公司 2024 年年度股东大会审议通过，公司决定 使用闲置自有资金额度不超过 20 亿元人民币进行现金管理，上述额度自股东大 会审议通过之日起 12 个月内有效，有效期内，上述额度可滚存使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《上海证券报》、《证券日报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 2、风险控制措施 公司将持续完善内部管理机制，保持合理现金储备，并通过审慎选择投资品 种、实施多元投资策略、执行流程约束、过程监控等方式降低或有风险。 一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 20,000 万元购买了部分理财 产 ...

Group 1 - The company has decided to deregister its wholly-owned subsidiary Heilongjiang Kuihua Pharmacy Co., Ltd. to optimize its investment holding system and reduce management layers [2][3] - The decision aims to achieve effective resource integration and cost reduction for concentrated development [2] - The deregistration process has been completed, and the company has received the deregistration notice from the Market Supervision Administration of Wuchang City [3] Group 2 - The deregistration of the subsidiary will not have a significant impact on the overall financial and operational situation of the company [3] - There are no adverse effects on the rights and interests of the company and all shareholders, particularly minority shareholders [3]

一、事项概述 证券代码：002737 证券简称：葵花药业 证券编号：2025-077 葵花药业集团股份有限公司 关于注销全资子公司的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 1、注销登记通知书 1 特此公告。 葵花药业集团股份有限公司 葵花药业集团股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日召开 第五届董事会第八次会议，审议通过《关于部分子（孙）公司注销及吸收合并的 议案》，公司基于优化投资控股体系，缩短管理链条，实现资源有效整合，降低 成本集约发展需求，决定注销全资子公司黑龙江葵花大药房有限公司（以下简称 "葵花大药房"）。 上述注销子公司事项的具体内容详见公司于 2025 年 7 月 26 日披露于《证券 日报》、《上海证券报》及巨潮资讯网（http:www.cninfo.com.cn）的相关公告 （公告编号 2025-041、2025-043）。 二、注销子公司进展情况 公司于近日办理完成葵花大药房的注销登记相关事项，并取得五常市市场监 督管理局下发的注销登记通知书。 此次注销全资子公司事项不会对公司整体财务、经营情 ...

Core Viewpoint - The announcement details the completion and termination of the 2022 employee stock ownership plan of Kew Flower Pharmaceutical Group Co., Ltd, highlighting the sale of all shares held under this plan and the associated performance metrics for unlocking shares [1][5]. Group 1: Employee Stock Ownership Plan Overview - The employee stock ownership plan was implemented in August 2022, with approval from the board and shareholders [1]. - A total of 2,950,060 shares were transferred to the employee stock ownership plan at a price of 7.50 yuan per share, representing 0.51% of the company's total share capital [2]. Group 2: Share Lock-up and Unlocking Conditions - The plan had a duration of 48 months, with shares unlocking in three phases based on performance metrics: 30% after 12 months, 35% after 24 months, and 35% after 36 months [3]. - The first two unlocking phases were successful, allowing for the release of 885,018 shares and 1,032,521 shares, respectively, while the third phase did not meet performance criteria, resulting in no shares being unlocked [3]. Group 3: Subsequent Arrangements Post-Plan - All shares under the employee stock ownership plan were sold through secondary market trading, completing the plan and leading to its early termination [5]. - The company will proceed with asset liquidation and distribution following the completion of the employee stock ownership plan [5].

Core Points - The company, Kewang Pharmaceutical, announced the completion of its employee stock ownership plan, with a total of 2,950,060 shares sold through the secondary market, representing 0.51% of the company's total share capital [2] Group 1 - The employee stock ownership plan was fully executed and terminated ahead of schedule, with subsequent asset liquidation and distribution processes to follow [2] - The company adhered to market trading rules and regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange during the implementation of the employee stock ownership plan [2] - No insider information was utilized for trading during the implementation period of the employee stock ownership plan [2]

证券代码：002737 证券简称：葵花药业 公告编号：2025-076 葵花药业集团股份有限公司 关于 2022 年员工持股计划股份出售完毕暨终止的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"葵花药业"）于 2022 年 8 月实施公司 2022 年员工持股计划，具体内容详见公司于 2022 年 8 月 24 日、 2022 年 9 月 10 日刊登在巨潮资讯网上的相关公告。目前，公司 2022 年员工持 股计划所持有的公司股份已全部售出完毕，根据《关于上市公司实施员工持股计 划试点的指导意见》、《葵花药业集团股份有限公司 2022 年员工持股计划（草 案）》等相关规定，现将相关情况公告如下： 一、本次员工持股计划的基本情况 公司于 2022 年 8 月 23 日召开第四届董事会第二十一次会议、第四届监事会 第十四次会议，并于 2022 年 9 月 9 日召开 2022 年第二次临时股东大会，审议通 过了《关于公司 2022 年员工持股计划（草案）及其摘要的议案》及相关议案。 2022 年 10 月 28 ...

Core Insights - On November 20, 2023, Kewah Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 30.31 million yuan [1] - The company reported a financing buy-in of 3.57 million yuan and a net financing buy of 1.38 million yuan on the same day [1] - As of November 20, the total margin balance for Kewah Pharmaceutical was 140 million yuan, indicating a low financing balance compared to the past year [1] Financing and Margin Data - Kewah Pharmaceutical's financing buy-in on November 20 was 3.57 million yuan, with a current financing balance of 138 million yuan, accounting for 1.60% of the circulating market value [1] - The company’s margin trading showed a repayment of 1,200 shares with no shares sold, resulting in a margin balance of 1.49 million yuan, which is also low compared to the past year [1] Company Overview - Kewah Pharmaceutical Group Co., Ltd. was established on September 7, 2005, and listed on December 30, 2014 [1] - The company specializes in the research, production, and sales of various traditional Chinese medicines and chemical drugs, with revenue composition as follows: traditional Chinese medicine 64.83%, chemical drugs 26.56%, nutritional health products 8.22%, and others 0.39% [1] Financial Performance - For the period from January to September 2025, Kewah Pharmaceutical reported a revenue of 1.684 billion yuan, a year-on-year decrease of 43.24%, and a net profit attributable to shareholders of -33.54 million yuan, a year-on-year decrease of 105.72% [2] Dividend Information - Since its A-share listing, Kewah Pharmaceutical has distributed a total of 4.045 billion yuan in dividends, with 1.752 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, Kewah Pharmaceutical had 53,000 shareholders, with an average of 11,018 circulating shares per person [2] - The top ten circulating shareholders include various ETFs, with notable changes in holdings among them [3]

Core Insights - The article highlights the successful participation of Sunflower Group at the 91st National Pharmaceutical Trade Fair and China International Health Nutrition Expo in Nanjing, where it showcased its brand "Wen Dong Fang" and won the "Innovation Pioneer - Industrial Enterprise Award" [3] Group 1: Company Achievements - Sunflower Group's health segment, in collaboration with its liquor division, has gained significant attention for its cross-industry innovation approach, emphasizing "brewing with a pharmaceutical heart" [3] - The "Wen Dong Fang" liquor has been well-received due to its pharmaceutical-grade quality control standards and the integration of traditional techniques with modern technology, leading to high demand and successful sales during the event [5] Group 2: Product Quality and Innovation - The "Wen Dong Fang" team undertook a three-year journey to select high-quality chestnuts from the "Hometown of Chinese Chestnuts" in Qianxi, Hebei, ensuring that each chestnut meets pharmaceutical-grade standards, with iron content in century-old trees being 2.1 times that of younger trees [9] - The production process combines traditional chestnut liquor brewing techniques with modern biological extraction technology, enhancing the absorption of herbal active ingredients while maintaining a low yield of 1 jin of liquor from 12 jin of chestnuts [9] Group 3: Market Positioning and Recognition - "Wen Dong Fang" is recognized as a pioneer in herbal chestnut liquor, catering to diverse consumer needs with products like "Wen Dong Fang No. 6" and "Wen Dong Fang No. 9," designed for casual drinking and gifting [9] - The brand has received authoritative recognition from industry experts and has been featured in a CCTV program, enhancing its credibility and public awareness [9][10]

Group 1 - The fifth meeting of the board of directors of Kew Flower Pharmaceutical Group Co., Ltd. was held on November 18, 2025, via telecommunication voting, with all nine directors participating [2][4]. - The board approved a proposal for product research and development, allocating up to 50 million yuan for projects including traditional Chinese medicine and generic drug development [3][5]. - The decision was made with unanimous support, receiving 9 votes in favor and no opposition or abstentions [4]. Group 2 - The meeting was convened by the chairwoman, Ms. Guan Yuxiu, and the notice and agenda were sent out on November 13, 2025 [2]. - The board's resolutions are valid and do not require submission to the shareholders' meeting for approval [5]. - The company ensures the accuracy and completeness of the information disclosed in the announcement [1].